试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
编号:NCT04155580登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:ASTX660、ASTX727
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
编号:NCT04637009登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:TAS1553
登记的停止原因(原文):termination due to portfolio prioritization
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
编号:NCT02780583登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:kineret、placebo
登记的停止原因(原文):no further funding to continue, investigator relocated, no replacement found to continue
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
编号:NCT03263091登记状态:提前终止企业 / 申办者:Kyntra Bio
药物 / 成分:Roxadustat、Placebo
登记的停止原因(原文):Study did not meet its primary efficacy endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
编号:NCT03318016登记状态:提前终止企业 / 申办者:University of Colorado, Denver
药物 / 成分:Cyclophosphamide 500 MG、Cyclophosphamide 1000 MG、Cyclophosphamide 2000 MG、Cyclophosphamide 3000 MG
登记的停止原因(原文):Low enrollment, University Scientific Review Committee required study closure.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction
编号:NCT03413891登记状态:提前终止企业 / 申办者:Universitaire Ziekenhuizen KU Leuven
药物 / 成分:Tranexamic Acid、Placebo
登记的停止原因(原文):Advice from DSMB
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Paracervical Injection for Headache in the Emergency Department
编号:NCT04109885登记状态:提前终止企业 / 申办者:Christian Fromm, MD
药物 / 成分:Paracervical injection、prochlorperazine and diphenhydramine.(Standard Treatment)
登记的停止原因(原文):Insufficient recruitment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Palbociclib + Ganitumab In Ewing Sarcoma
编号:NCT04129151登记状态:提前终止企业 / 申办者:Dana-Farber Cancer Institute
药物 / 成分:Palbociclib、Ganitumab
登记的停止原因(原文):The study closed early due to discontinuation of ganitumab supply.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
编号:NCT04395339登记状态:提前终止企业 / 申办者:Sun Yat-sen University
药物 / 成分:Monosialotetrahexosyl ganglioside (GM1)、Control
登记的停止原因(原文):Difficulty accruing subjects the study accrual was closed
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
编号:NCT04629781登记状态:提前终止企业 / 申办者:Swiss Cancer Institute
药物 / 成分:Docetaxel micellar
登记的停止原因(原文):SAKK decided to premature terminate this trial as additional follow-up visits do not further contribute to the efficacy data. This decision does not adversely impact the patients.
查看官方原始记录 ↗